Literature DB >> 9731863

Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies.

J R Higgins1, J J Walshe, M R Darling, L Norris, J Bonnar.   

Abstract

OBJECTIVE: Our purpose was to determine the hemostatic changes in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. STUDY
DESIGN: This prospective, observational study involved 2 patient groups. Group 1 consisted of 30 normotensive women and 22 women with pre-eclampsia who were followed up longitudinally through pregnancy and post partum. Group 2 consisted of 20 women with established pre-eclampsia and 19 normotensive control subjects, all undergoing cesarean section. Plasma levels of thrombin-antithrombin III complex, soluble fibrin, plasmin-alpha2-antiplasmin complex, and fibrin-degradation product (D-dimer) were measured in blood drawn from the antecubital vein (group 1) and from both the antecubital and uterine veins (group 2). Data were analyzed by analysis of variance.
RESULTS: In group 1 levels of thrombin-antithrombin III complex, soluble fibrin, and fibrin-degradation product were significantly higher during normal pregnancy than at 6 weeks post partum. Plasmin-alpha2-antiplasmin complex levels did not change. No differences between the pre-eclamptic and normotensive pregnancy groups were found for any of the hemostatic markers. In group 2 normotensive women undergoing cesarean section, thrombin-antithrombin III complex and soluble fibrin levels were significantly higher in the uterine vein than in the antecubital vein. In group 2 women with pre-eclampsia, thrombin-antithrombin III complex and fibrin-degradation product levels were significantly higher in the uterine vein than in the antecubital vein. In addition, plasmin-alpha2-antiplasmin complex and fibrin-degradation product levels were higher and soluble fibrin levels were lower in the uterine vein in the pre-eclamptic group than in the normotensive group.
CONCLUSION: Both the coagulation and fibrinolytic systems are activated during normal pregnancy. Activation of these systems is more marked in the uteroplacental circulation than in the systemic circulation in both normotensive and pre-eclamptic pregnancies. An abnormal pattern of hemostasis occurs in the uteroplacental circulation in pre-eclampsia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731863     DOI: 10.1016/s0002-9378(98)70389-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

Review 1.  Association of microparticles and preeclampsia.

Authors:  Fabiana K Marques; Fernanda M F Campos; Lirlândia P Sousa; Andréa Teixeira-Carvalho; Luci M S Dusse; Karina B Gomes
Journal:  Mol Biol Rep       Date:  2013-05-06       Impact factor: 2.316

2.  Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes.

Authors:  Offer Erez; Roberto Romero; Edi Vaisbuch; Nandor Gabor Than; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Pooja Mittal; Zhong Dong; Tinnakorn Chaiworapongsa; Chong Jai Kim; Chia-Ling Nhan-Chang; Sun Kwon Kim; Lami Yeo; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2017-05-19

3.  Coagulation and Fibrinolytic System Protein Profiles in Women with Normal Pregnancies and Pregnancies Complicated by Hypertension.

Authors:  Sarah A Hale; Burton Sobel; Anna Benvenuto; Adrienne Schonberg; Gary J Badger; Ira M Bernstein
Journal:  Pregnancy Hypertens       Date:  2012-04-01       Impact factor: 2.899

4.  Preeclampsia: the role of tissue factor and tissue factor pathway inhibitor.

Authors:  Lara Carvalho Godoi; Karina Braga Gomes; Patrícia Nessralla Alpoim; Maria das Graças Carvalho; Bashir A Lwaleed; Luci Maria Sant'Ana Dusse
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

5.  Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Juan Pedro Kusanovic; Eleazar Soto; Jennifer Lam; Zhong Dong; Nandor G Than; Lami Yeo; Edgar Hernandez-Andrade; Agustín Conde-Agudelo; Sonia S Hassan
Journal:  Am J Obstet Gynecol       Date:  2013-01-17       Impact factor: 8.661

6.  Thrombin activatable fibrinolysis inhibitor in preeclampsia and gestational hypertension throughout the gestation.

Authors:  Yinghong Zhang; Yu Hu; Tao Guo; Wenning Wei; Xiaoping Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-05-15

7.  Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Francesca Gotsch; Jimmy Espinoza; Jyh Kae Nien; Luis Goncalves; Samuel Edwin; Yeon Mee Kim; Offer Erez; Juan Pedro Kusanovic; Beth L Pineles; Zoltan Papp; Sonia Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2008-01

Review 8.  Preeclampsia and ABO blood groups: a systematic review and meta-analysis.

Authors:  Patricia Nessralla Alpoim; Melina de Barros Pinheiro; Daniela Rezende Garcia Junqueira; Leticia Gonçalves Freitas; Maria das Graças Carvalho; Ana Paula Salles Moura Fernandes; Flávia Komatsuzaki; Karina Braga Gomes; Luci Maria Sant'Ana Dusse
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

9.  Are the blood groups of women with preeclampsia a risk factor for the development of hypertension postpartum?

Authors:  Deniz Avci; Hatice Karagoz; Ozerhan Ozer; Kubra Esmeray; Kadir Bulut; Fatma Aykas; Ali Cetinkaya; Emine Uslu; Samet Karahan; Mustafa Basak; Abdulsamet Erden
Journal:  Ther Clin Risk Manag       Date:  2016-04-19       Impact factor: 2.423

10.  Fibrinolytic proteins of normal pregnancy and pre-eclamptic patients in North West Nigeria.

Authors:  Oluwatosin Oladosu-Olayiwola; Hannah Olawumi; Abiola Babatunde; Munirdeen Ijaiya; Idayat Durotoye; Sikiru Biliaminu; Rasheedat Ibraheem
Journal:  Afr Health Sci       Date:  2018-09       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.